Table 2. Multivariate logistic analysis to identify the factors associated with failure to achieve HBV viral suppression (<128 copies/ mL) after 48 weeks of tenofovir-containing antiretroviral therapy.
| Variablea | Achieve viral suppression (n = 78) | Failure to achieve viral suppression (n = 11) | Logistic Regression | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | Univariate p = | OR (95% CI) | Multivariate p = | |||
| Age, years | 39 ± 8 | 34 ± 7 | 0.931 (0.853–1.016) | 0.107 | 0.900 (0.806–1.003) | 0.058 |
| HBV genotype B | 56/65 (86.2) | 9/11 (81.8) | 0.723 (0.134–3.904) | 0.706 | ||
| Lamivudine resistance of HBV | 27 (34.6) | 6 (54.5) | 2.267 (0.633–8.113) | 0.208 | 4.429 (0.894–21.946) | 0.068 |
| CD4 count at baseline, cells/μl | 360 ± 334 | 375 ± 251 | 1.000 (0.998–1.002) | 0.884 | ||
| Plasma HIV RNA load at baseline, log10 copies/mL | 3.8 ± 1.6 | 3.1 ± 1.6 | 0.770 (0.521–1.139) | 0.191 | ||
| Plasma HBV DNA load at baseline, log10 copies/mL | 5.7 ± 2.1 | 8.1 ± 1.3 | 1.875 (1.223–2.874) | 0.004 | 1.861 (1.204–2.878) | 0.005 |
| HBsAg level at baseline, log10 IU/mL | 4.1 ± 1.8 (n = 61) | 5.8 ± 1.5 (n = 10) | 1.680 (1.141–2.474) | 0.009 | ||
| Positive HBeAg at baselineb | 23/77 (29.9) | 11/11 (100) | ||||
Results are n (%), or mean ± standard deviation.
Abbreviations: HBV, hepatitis B virus; HBeAg, HBV envelope antigen; HBsAg, HBV surface antigen; CI, confidence interval; OR, odds ratio.
aVariables considered for entry into multivariate logistic regression model included variables with P values <0.25 in univariate analysis.
b All patients failing to achieve viral suppression had positive HBeAg at baseline and, therefore, the factor was not included in the logistic regression.